Holen Sie sich die Stockscreener-App
44.50
5.38%
-2.53
Handel nachbörslich:
45.15
0.65
+1.46%
Schlusskurs vom Vortag:
$47.03
Offen:
$46.3
24-Stunden-Volumen:
717.16K
Relative Volume:
1.20
Marktkapitalisierung:
$807.73M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-317.86
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+3.90%
1M Leistung:
+2.53%
6M Leistung:
+141.59%
1J Leistung:
+173.85%
1-Tages-Spanne:
$43.10
$46.75
1-Wochen-Bereich:
$40.50
$49.10
52-Wochen-Spanne:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
44.50 | 853.66M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - ulpravda.ru
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - simplywall.st
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio - The Manila Times
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030Rigel Pharmaceuticals Lea - PharmiWeb.com
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - StreetInsider
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance - Yahoo Finance
Technical Reactions to RIGL Trends in Macro Strategies - Stock Traders Daily
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Year in Review & Growth Focused Entry Reports - moha.gov.vn
What analysts say about Rigel Pharmaceuticals Inc RI2 stockLow Beta Stocks & Low Risk Investment Growth - earlytimes.in
Jhandewalas Foods Limited Earnings Review What Investors Need to KnowHigh Dividend Yield Stocks & See Risk Factors Before Making Any Move - earlytimes.in
Rigel Pharma: Formulating A Game Plan For 2026 - Seeking Alpha
Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC - MarketBeat
Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) CFO reports multiple option exercises and share ownership - Stock Titan
Rigel Pharmaceuticals: Formulating A Game Plan For 2026 (NASDAQ:RIGL) - Seeking Alpha
Rigel enrols first subject in Phase I sickle cell disease therapy trial - MSN
With EPS Growth And More, Rigel Pharmaceuticals (NASDAQ:RIGL) Makes An Interesting Case - Yahoo Finance
Inspire Investing LLC Makes New $859,000 Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Momentum Shift: Will Rigel Pharmaceuticals Inc RI2 stock beat Nasdaq index returnsInsider Selling & Free Growth Oriented Trading Recommendations - moha.gov.vn
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 23% Below Their Intrinsic Value Estimate - 富途牛牛
Assenagon Asset Management S.A. Decreases Holdings in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
(RIGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rigel Pharmaceuticals (NASDAQ:RIGL) Upgraded to Buy at Wall Street Zen - MarketBeat
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - MSN
Can Rigel Pharmaceuticals Inc. stock deliver sustainable ROEJuly 2025 Snapshot & Weekly High Return Opportunities - Улправда
Will Rigel Pharmaceuticals Inc. stock benefit from automationEarnings Growth Report & Consistent Growth Stock Picks - DonanımHaber
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
How Rigel Pharmaceuticals Inc. stock compares to market leadersJuly 2025 Breakouts & High Accuracy Trade Alerts - DonanımHaber
Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891 - MSN
Rigel Pharmaceuticals Earnings Notes - Trefis
Rigel Pharmaceuticals reports promising Phase 1b study results - MSN
Behavioral Patterns of RIGL and Institutional Flows - news.stocktradersdaily.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Rigel Pharma downgraded by Piper Sandler with a new price target - Quantisnow
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m - simplywall.st
Rigel Pharmaceuticals, Inc. $RIGL Shares Bought by Globeflex Capital L P - MarketBeat
Armistice Capital LLC Acquires 84,000 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Top-Rated Stocks: Rigel Pharmaceuticals Sees Composite Rating Climb To 96 - MSN
Rigel Pharmaceuticals Reports Promising Phase 1b Study Results - TipRanks
Rigel Pharmaceuticals Inc Presents Updated Data from Phase 1b Study on R289 - TradingView — Track All Markets
Rigel Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 13.7%Should You Sell? - MarketBeat
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (RIGL) is a great momentum stock: Should you buy? - MSN
Rigel Pharmaceuticals (RIGL) Shares Promising Data from Phase 1b Study - GuruFocus
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - Lelezard
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):